Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter

Abstract

In HIV-infected patients with little or no prior antiretroviral therapy, treatment with a combination of lamivudine and zidovudine is well tolerated over a one-year period and produces more improvement in immunologic and virologic measures than does treatment with either agent alone.

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial

“…This conclusion is supported by earlier studies of lamivudine, which demonstrated greater and more durable responses to lamivudine plus zidovudine in terms of CD4-count increases and viral-load decreases in patients who had received no previous antiretroviral treatment, than in patients who had received previous zidovudine therapy. [5][6][7][8] These data together support the conclusion that a combination of lamivudine plus zidovudine will provide the greatest clinical benefit to patients who have not previously received other antiretroviral therapies.…”

“…[1][2][3][4] Combination treatment with lamivudine (Glaxo Wellcome) plus zidovudine (Glaxo Wellcome) caused pronounced and sustained increases in CD4-cell counts and reductions in HIV-1 viral load in four separate studies, done in both previously antiretroviral untreated and pretreated HIV-1-positive patients. [5][6][7][8] Meta-analysis of these four studies showed that these treatment-induced changes in CD4 count and viral load were associated with a reduction in disease progression. 9 Because these studies were done in relatively healthy patients (CD4 range 100-500/µL) the majority of clinical events included in this meta-analysis were the development of Centers for Disease Control and Prevention Stage B (CDC B) AIDSrelated complex events in patients who were symptom free at baseline.…”

HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial

“…Similar changes have been described in two other shortterm, virological-endpoint trials studying combinations of two nucleoside reverse-transcriptase inhibitors. 20,21 The Wellcome Resistance Study Collaboration Group 22 followed a similar protocol to Delta 1 (with half the didanosine dose) and also found only a low frequency of both resistant mutations and isolates with decreased susceptibility to didanosine and zalcitabine in the combined-therapy groups. There were no differences found in the evolution of zidovudine mutations at codon 215 in the three treatment groups.…”

Simultaneous Estimation of Lamivudine, Abacavir and Dolutegravir by Uplc Method

“…Lamivudine administered orally, it is rapidly absorbed with a bioavailability of 80% to 87%. FDA approval granted in 1995 for lamivudine to use pediatric and adult based on increases in CD4 T-lymphocyte count [8] on a regimen of zidovudine and lamivudine compared with either drug alone or compared with a combination of zalcitabine and zidovudine was initial approval [9]. Lamivudine is in combinations with several triple nucleoside analogues has been shown to lead to high virologic failure in previously untreated individuals [10][11][12][13].…”